BioNJ welcomes Leerink Swan as a new Diamond Member for 2011:
Founded in 1995, Leerink Swann is recognized as a leading healthcare investment bank to a broad range of institutional, life sciences, corporate, and high-net-worth clients that are positioned to shape the future of healthcare. Leerink Swann’s deep domain knowledge provides its clients thoroughly researched insights and perspectives that enable them to make well-informed investment and business decisions. All of its services are enhanced by the expertise of its proprietary MEDACorp network. MEDACorp’s 35,000+ physicians, researchers, and healthcare professionals provide unparalleled insights into cutting-edge advances in healthcare. Guided by expert strategy and insight, Leerink Swann offers investment banking, merger and acquisition services, institutional sales and trading, equity research, consulting, and wealth management. Leerink Swann is a member of FINRA/SIPC.
BioNJ welcomes our new Core Members for 2011:
Argyle Therapeutics, Inc.
Argyle Therapeutics, Inc. (“Argyle”) is a biopharmaceutical company focused on the discovery and development of innovative products to address major medical needs in the field of dermatology. Argyle develops synthetic compounds that are mimetics of natural lipid ligands crucial to cellular regulation and signaling. The novel mechanism of action and superior safety profiles makes them highly promising drug candidates. These proprietary New Chemical Entities (NCEs) have significant pharmaceutical potential for treating regulatory dysfunctions underlying inflammatory skin diseases. The worldwide prescription market that is being targeted amounts to over $14 billion and includes major inflammatory diseases such as: acne, atopic dermatitis, psoriasis, and rosacea as well as the rapidly expanding area of prescription aesthetics. The company has also identified compounds that will be out-licensed for use in a diverse array of cosmetic applications. Argyle has strategically selected these industry segments that have had annual growth rates of 6 to 8 percent and should continue for the foreseeable future.
Senesco Technologies, Inc.
SENESCO TECHNOLOGIES, INC. (NYSE Amex: SNT) is a cancer therapeutics company leveraging its strong proprietary position in eukaryotic translation initiation Factor 5A (eIF5A) technology to regulate programmed cell death, also known as apoptosis. eIF5A modulation has been effective in all human cancer cells tested so far and against human multiple myeloma tumors in animal models. The company is preparing to initiate a clinical program in multiple myeloma patients with its lead therapeutic candidate SNS01-T. SNS01-T incorporates recent developments in siRNA, DNA regulation, and nanotechnology. Senesco is building its portfolio with other potential eiF5A applications in cancer, inflammation and ischemia. For more information, click here or contact Les Browne at (908) 864-4444.
BioNJ welcomes our new Associate Members for 2011:
MARKETPLAZA – Innovation Managers
With offices in Latin America (Uruguay and Costa Rica), our Marketplaza group is dedicated to bringing the right people and stakeholders together to produce innovation. We carry out alliance management services for companies from around the world interested in our network of biotechnology companies, researchers, and government representatives within Latin America.
Since 2010, in Costa Rica, our company has been hired by CINDE (Costa Rica’s foreign investment promotion agency) to develop the strategy and promote the establishment of foreign biotechnology companies in the country and promote partnerships with local organizations. We represented the country at BIO-EUROPE in Milan (March 2011) and at BIO 2010 and 2011.
Our President, Gabriela Couto, formerly worked at National Biotechnology Innovation Center of Costa Rica, Institut Pasteur de Montevideo, Biotechnology Center at the National Institute of Agronomic Research of Uruguay, and Technology Management Center of the Uruguayan Chamber of Industries. He maintains contact with government, academy, and biotech companies in Argentina, Brazil, Chile, and Uruguay.
Novoprotein Scientific Inc.
Novoprotein is a leading contract research biotech company dedicated solely to recombinant protein service. Novoprotein offers a comprehensive service portfolio, from protein expression, antibody production, protein modification, and protein crystallization. Novopotein has accomplished over 1,000 contract projects with an 85 percent success rate, and has developed a catalog of more than 500 enzymes and cytokines since its inception in 2004. The capacity of the four well-established protein expression systems, E. coli, yeast, baculovirus/insect cell, and mammalian cell systems, have reached gram scale. Novoprotein’s facility is certified by ISO9001:2008 quality management system, and their long-term clients are from organizations across the world.
Provonix is a contract research organization specializing in analyzing and reporting clinical trial data. We have worked in many therapeutic areas, for all phases of trials, and have significant experience in setting up and conducting clinical trials. It is our attention to detail and expertise in statistical planning, analysis, programming, and reporting that set us apart from other CROs.
Provonix offers individualized, affordable clinical trial support. Specifically, the services we provide are Biostatistical Consulting, SAS programming, Data Management, Medical Writing, and Pharmacokinetic Analysis. We are located in the Rohrer College of Business Incubator at Rowan University, in Glassboro, NJ.
Science Care is the world’s leading non-transplant tissue bank and the first to be accredited by the American Association of Tissue Banks. We provide human tissue for medical research and education, offer safe and secure medical training facilities, continuing medical education, outcomes measurement, and events management, all benefiting patient quality of life. Our newest medical training facility is in Jamesburg and can accommodate a multitude of training lab opportunities. To learn more, click here.
Hemispherx Biopharma, Inc.
Hemispherx Biopharma, based in Philadelphia with manufacturing in New Brunswick, is a biopharmaceutical company engaged in the manufacture and clinical development of new drug entities for treatment of viral and immune-based disorders. Hemispherx’s flagship products include FDA-approved Alferon N Injection® and the experimental immunotherapeutics/antivirals Ampligen®, currently under FDA review for the approval of chronic fatigue syndrome, and Oragens®.
BioNJ thanks our Associate Members that have renewed their membership for 2011:
Biologics Consulting Group, Inc.
Biologics Consulting Group specializes in the preparation and review of CBER regulatory applications (INDs and BLAs) as well as the inspection/audit of biologics manufacturing facilities but also in similar regulatory activities for drugs, devices, and combination products.
Toxikon is a preclinical contract research organization. We contract and partner with biotech, pharmaceutical, and medical device industries to deliver exceptional product development services from concept to final products. With approximately 200 employees, Toxikon is committed to staying at the forefront of biotech product development. Toxikon’s safety services include toxicology (acute, subchronic, and chronic toxicity, reproductive toxicity, genetic toxicology, and carcinogenicity), pharmacokinetics, toxicokinetics, bioavailability, ADME, chemical characterization, impurities analysis and synthesis, bioanalysis, and microbiology.